The cardioprotective benefit and anti cancer synergy will certainly get FDA attention with the newly developed formulation and will likely come but in due course.... the 505(b)2 pathway is no longer appealing due to the longer IP life of RC220. Breakthrough designation would be a more relevant possibility.
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-91
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.88 |
Change
0.025(1.35%) |
Mkt cap ! $319.4M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.89 | $1.85 | $74.38K | 39.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18943 | $1.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |